A5014644902- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Pneumonia and Respiratory Infections
- Viral Infections and Immunology Research
- Rabies epidemiology and control
- Toxoplasma gondii Research Studies
- Energy Harvesting in Wireless Networks
- Herpesvirus Infections and Treatments
Université Laval
2020-2024
Inserm
2024
École Normale Supérieure de Lyon
2024
Université Claude Bernard Lyon 1
2021-2024
Centre hospitalier universitaire de Québec
2020-2024
Centre National de la Recherche Scientifique
2024
Virologie et Pathologies Humaines
2021
Abstract Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses have the potential to protect against Respiratory Syncytial Virus (RSV) Human Metapneumovirus (HMPV), main etiologic agents of viral bronchiolitis pneumonia in children. We inserted RSV-F gene into an HMPV-based LAV (Metavac®) we previously validated for protection mice HMPV challenge, rescued a replicative recombinant virus (Metavac®-RSV), exposing both RSV- HMPV-F proteins at virion surface expressing...
The development of a live-attenuated vaccine (LAV) for the prevention human metapneumovirus (HMPV) infection is often hampered by lack highly efficient and scalable cell-based production systems that support eventual global production. Avian cell lines cultivated in suspension compete with traditional platforms used viral manufacture. We investigated whether DuckCelt®-T17 avian line (Vaxxel), previously described as an system several influenza strains, could also be to produce new HMPV LAV...
is a ubiquitous parasite causing significant mortality in captive wildlife, especially marsupials. Historically, treatment has been unrewarding and no vaccine was available. An intranasal based on purified inactivated
Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses have the potential to protect against Respiratory Syncytial Virus (RSV) Human Metapneumovirus (HMPV), main etiologic agents of viral bronchiolitis pneumonia in children. We inserted RSV-F gene into a HMPV-based LAV (Metavac®) we previously validated for protection mice HMPV challenge, rescued replicative recombinant virus (Metavac®-RSV), exposing both RSV- HMPV-F proteins at its surface expressing them...
<title>Abstract</title> Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses have the potential to protect against Respiratory Syncytial Virus (RSV) Human Metapneumovirus (HMPV), main etiologic agents of viral bronchiolitis pneumonia in children. We inserted RSV-F gene into an HMPV-based LAV (Metavac®) we previously validated for protection mice HMPV challenge, rescued a replicative recombinant virus (Metavac®-RSV), exposing both RSV- HMPV-F proteins at its surface...
Abstract Human metapneumovirus (HMPV) is a major pediatric respiratory pathogen for which there currently no specific treatment or licensed vaccine. Different strategies have been evaluated to prevent this infection, including the use of live-attenuated vaccines (LAVs). However, further development LAV approaches often hampered by lack highly efficient and scalable cell-based production systems that support worldwide vaccine production. In context, avian cell lines cultivated in suspension...